
The FDA approved the oral SERD giredestrant with everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer based on phase 3 evERA data.
Pierre Gholam, MD, provides insight on the case of a 61-year-old man with stage 4 hepatocellular carcinoma and evaluates current treatment options on TKIs.
Case: A 61-Year-Old Man with Stage 4 Hepatocellular Carcinoma
Initial presentation
Clinical workup
Treatment and Follow-Up






